Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBITDA (2016 - 2026)

Summit Therapeutics filings provide 13 years of EBITDA readings, the most recent being -$189.5 million for Q1 2026.

  • Quarterly EBITDA fell 199.91% to -$189.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Mar 2026, down 400.96% year-over-year, with the annual reading at -$1.1 billion for FY2025, 388.28% down from the prior year.
  • EBITDA hit -$189.5 million in Q1 2026 for Summit Therapeutics, up from -$219.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$15.8 million in Q2 2023 and bottomed at -$565.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$128.5 million, with a median of -$56.1 million recorded in 2024.
  • The largest annual shift saw EBITDA plummeted 2240.02% in 2023 before it skyrocketed 91.98% in 2024.
  • Summit Therapeutics' EBITDA stood at -$17.9 million in 2022, then crashed by 104.93% to -$36.7 million in 2023, then plummeted by 66.74% to -$61.2 million in 2024, then tumbled by 257.97% to -$219.0 million in 2025, then increased by 13.46% to -$189.5 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's EBITDA are -$189.5 million (Q1 2026), -$219.0 million (Q4 2025), and -$231.8 million (Q3 2025).